The result of the study showed positive relationship between the bone scan findings and CA 15-3 level of carcinoma breast patients.
INTRODUCTION
Bone metastasis is very common in breast cancer affecting approximately 70% of patient (1, 2) . The detection of bone metastasis accurately reflects the prognosis and the early detection in the asymptomatic case may alert the clinician to the possible complications inherit in skeletal destruction (3, 4) . Radioisotope bone scintigraphy is the most sensitive and the most common method for screening bony metastasis (5, 6) .
Carbohydrate antigen 15-3 (CA 15-3) is a tumor marker commonly used in the screening breast cancer patients for metastasis and monitoring treatment response (7, 8, 9) . The aim of this study was to find out the relation between bone metastasis and CA15-3.
PATIENTS AND METHODS
This analytical cross sectional study was carried out in the Institute of Nuclear Medicine and Allied Sciences, Mitford, Dhaka from January 2015 to December 2015.
Total 75 histologically proven cases of primary carcinoma breast patient were enrolled in this study. 
RESULTS
Total 75 primary carcinoma patients with mean ± SD age 47.60 ± 10.53 years (range, 25 to 65 years) were enrolled in this study. The bar diagram showed the distribution of the carcinoma breast patients at different age groups (Figure 1 ). About half (49%) patients belonged to age group 50 years and above.
Figure 1: Bar diagram of distribution the carcinoma patients in different age groups.
In this study, the mean ± SD of CA15.3 level was 84.06 ± 104.60 U/ml, ranging from 10.12 to 395.30 U/ml. Out of 75 patients, serum CA15-3 was within normal limit in 42(56%), elevated in 33(44%) patients and bone scan was negative for metastasis in 44(58.7%) patients and positive for metastasis in 31(41.3%) patients.
Among 42 patients with normal CA 15-3 level, bone scan was negative for metastasis in 30 patients (mean ± SD of CA 15.3 was 18.26 ± 5.54 U/ml) and positive for metastasis in 12 patients (mean ± SD of CA 15.3 was 19.55 ± 5.1) (Table 1.). Similarly out of 33 patients with elevated serum CA 15-3, bone scan was negative for metastasis in 14 patients (mean ± SD of CA 15.3 was 60.98 ± 9.95 U.ml) and positive for metastasis in 19 patients (mean ± SD of CA15.3 was 246.23 ± 81.35 U/ml) (Table 2.). This might be due to the decreased net half life of collagen after menopause (5, 6, 9) . In this study about half (49%) of the patients belonged to age group 50 years and above. Prognosis is strongly related with the extent of the disease. Bone scintigraphy is used in the management of breast carcinoma with high sensitivity and limited specificity (11, 12) . Elevated CA 15-3 tumor markers sometimes provide evidence on undiagnosed metastasis in patients with breast cancer (11, 12, 13) .
In this study, out of 75 patients, 42(56%) had normal CA 
CONCLUSION
This study showed positive correlation between CA 15-3 level and Bone scan findings in patients with breast cancers. Therefore, CA 15-3 level tumor marker can be used as a preliminary tool for screening to select patients who needs radionuclide bone scan.
